ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the 100 Best Medium Workplaces based on an independent survey by Fortune Magazine and Great Place to Work®. The survey included more than 52,000 employees at over 450 companies based in the United States. Companies included on the list showed strong corporate culture, a commitment to employee benefits, a deep engagement among employees, and a clear sense of mission.
“We’re gratified to receive this recognition. Our associates have established a culture that values trust, collaboration and open communication. This culture is an extension of our mission to develop therapies that improve the lives of people with neurological disorders,” said Ron Cohen, M.D., Acorda's President and CEO. “Developing new, life-changing medicines is an incredibly challenging undertaking, which our associates embrace. Being able to come to work with like-minded individuals, in a supportive, rewarding and fun environment, helps us to stay focused on that mission.”
In addition to being named one of the Best Medium Workplaces, Acorda was also recognized by Fortune and Great Place to Work in 2016 as one of the Best Workplaces for Women (second year in a row), as well as Best Workplaces for Baby Boomers and Best Workplaces for Millennials. The Company has also been recognized as one of the Best Places to Work in New York for six consecutive years by the Best Companies Group, ranking 3rd in 2016 among employers with more than 250 associates. These recognitions highlight Acorda’s commitment to creating an inclusive and diverse workplace that values the contributions of all associates.
The Best Medium Workplaces list was determined by surveying employees on factors such as their feelings on management’s credibility, the degree of support for employees' personal and professional lives, employees’ overall job satisfaction, and sense of camaraderie. Fortune and Great Place to Work also assessed corporate culture, salary and benefit programs, hiring practices, internal communication, training, recognition programs, and diversity efforts in determining the final rankings.
For more information on careers at Acorda, please visit http://www.acorda.com/careers.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.
Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, post-stroke walking difficulties, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
For more information, please visit the Company’s website at: www.acorda.com.
This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: the ability to complete the Biotie transaction on a timely basis; the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the ability to successfully integrate Biotie’s operations and Civitas’ operations, respectively, into our operations; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; our ability to successfully market and sell Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301 or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, any other products under development, or the products that we will acquire when we complete the Biotie transaction; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain and maintain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaborator Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this presentation are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.